Literature DB >> 29444943

Vaccinia Virus C9 Ankyrin Repeat/F-Box Protein Is a Newly Identified Antagonist of the Type I Interferon-Induced Antiviral State.

Ruikang Liu1, Bernard Moss2.   

Abstract

Type I interferons (IFNs) induce expression of more than 300 cellular genes that provide protection against viruses and other pathogens. For survival, viruses evolved defenses to prevent the IFN response or counteract the IFN-induced antiviral state. However, because viruses and cells coevolved, the dynamic relationship between virus and host is difficult to discern. In the present study, we demonstrated that vaccinia virus with a large deletion near the left end of the genome had a diminished ability to replicate in cells that had been pretreated with beta interferon (IFN-β), suggesting that one or more of the missing 17 open reading frames (ORFs) encode an antagonist of the IFN-induced antiviral state. By systematically deleting groups of ORFs and then individual ORFs, the C9L gene was shown to be required for IFN resistance. Replication of the C9L deletion mutant (vΔC9) was impaired in human cells that had been pretreated with IFN-β. Expression of viral early genes occurred, but subsequent events, including genome uncoating, genome replication, and postreplicative gene expression, were inhibited. Expression of the C9 protein occurred prior to genome replication, consistent with an early role in counteracting the IFN-induced antiviral state. C9 contains six ankyrin repeat motifs and a near C-terminal F-box. Mass spectrometry and immunoblotting identified host proteins that copurified with a functional epitope-tagged C9. The most abundant proteins were components of the SCF (CUL1, SKP1, F-box) and signalosome/deneddylation complexes, which interact with each other, suggesting a possible role in proteolysis of one or more interferon-induced proteins.IMPORTANCE Poxviruses comprise a family of large DNA viruses that replicate in the cytoplasm of vertebrate and insect hosts and cause human and zoonotic diseases. In most cases the primary infection is moderated by innate immune defenses. Vertebrates, including fish, amphibians, reptiles, birds, and mammals, all produce type I interferon homologs. In humans, interferon stimulates the synthesis of more than 300 proteins thought to have roles in host defense. Conversely, viruses have evolved means to thwart the host defenses. We are attempting to deconstruct the established virus-host relationship in order to better understand the molecular mechanisms involved. In the present study, we identified a vaccinia virus gene that prevents interferon-mediated inhibition of very early stages of viral replication and is conserved in orthopoxviruses. The viral protein was shown to interact with host proteins involved in proteolysis, suggesting that vaccinia virus may subvert the cellular apparatus for its own defense.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  SCF complex; SKP1; cullin 1; deneddylation; interferon; orthopoxvirus; poxvirus; signalosome

Mesh:

Substances:

Year:  2018        PMID: 29444943      PMCID: PMC5899206          DOI: 10.1128/JVI.00053-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

Review 1.  Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response.

Authors:  Robert H Silverman
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

2.  SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses.

Authors:  Jia Liu; Grant McFadden
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

3.  Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses.

Authors:  Jeffrey L Americo; Patricia L Earl; Bernard Moss
Journal:  Virology       Date:  2017-08-10       Impact factor: 3.616

4.  Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65.

Authors:  B Sodeik; G Griffiths; M Ericsson; B Moss; R W Doms
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase.

Authors:  K Carroll; O Elroy-Stein; B Moss; R Jagus
Journal:  J Biol Chem       Date:  1993-06-15       Impact factor: 5.157

6.  Intermolecular duplexes formed from polyadenylylated vaccinia virus RNA.

Authors:  R F Boone; R P Parr; B Moss
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

7.  Expression profiling of the intermediate and late stages of poxvirus replication.

Authors:  Zhilong Yang; Sara E Reynolds; Craig A Martens; Daniel P Bruno; Stephen F Porcella; Bernard Moss
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

8.  Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant.

Authors:  G J Kotwal; B Moss
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

9.  A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies.

Authors:  E J Wolffe; S Vijaya; B Moss
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

10.  Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR-Cas9 Knockout Cell Lines and Vaccinia Virus Mutants.

Authors:  Ruikang Liu; Bernard Moss
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

View more
  11 in total

1.  Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus.

Authors:  Tatiana G Senkevich; Erik K Zhivkoplias; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

2.  Loss of the vaccinia virus 35-amino acid hydrophobic O3 protein is partially compensated by mutations in the transmembrane domains of other entry proteins.

Authors:  Andrew I Tak; Jeffrey L Americo; Ulrike S Diesterbeck; Bernard Moss
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

3.  Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.

Authors:  Alexandria C Linville; Amber B Rico; Helena Teague; Lucy E Binsted; Geoffrey L Smith; Jonas D Albarnaz; Matthew S Wiebe
Journal:  J Virol       Date:  2022-05-11       Impact factor: 6.549

Review 4.  Immune Ecosystem of Virus-Infected Host Tissues.

Authors:  Mohamed Maarouf; Kul Raj Rai; Mohsan Ullah Goraya; Ji-Long Chen
Journal:  Int J Mol Sci       Date:  2018-05-06       Impact factor: 5.923

5.  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Authors:  Patricia Kleinpeter; Christelle Remy-Ziller; Eline Winter; Murielle Gantzer; Virginie Nourtier; Juliette Kempf; Julie Hortelano; Doris Schmitt; Huguette Schultz; Michel Geist; Catherine Brua; Chantal Hoffmann; Yasmin Schlesinger; Dominique Villeval; Christine Thioudellet; Philippe Erbs; Johann Foloppe; Nathalie Silvestre; Laetitia Fend; Eric Quemeneur; Jean-Baptiste Marchand
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

6.  Vaccinia Virus Ankyrin-Repeat/F-Box Protein Targets Interferon-Induced IFITs for Proteasomal Degradation.

Authors:  Ruikang Liu; Lisa R Olano; Yeva Mirzakhanyan; Paul D Gershon; Bernard Moss
Journal:  Cell Rep       Date:  2019-10-22       Impact factor: 9.423

Review 7.  Vaccinia Virus as a Master of Host Shutoff Induction: Targeting Processes of the Central Dogma and Beyond.

Authors:  Pragyesh Dhungel; Fernando M Cantu; Joshua A Molina; Zhilong Yang
Journal:  Pathogens       Date:  2020-05-21

Review 8.  Repurposing approved drugs on the pathway to novel therapies.

Authors:  Catherine H Schein
Journal:  Med Res Rev       Date:  2019-08-20       Impact factor: 12.944

9.  Genomic diversity of vaccinia virus strain Cantagalo isolated in southeastern Brazil during the early years of the outbreak, 1999-2006.

Authors:  Aline Rv Souza; Matheus Nobrega Luques; Clarissa R Damaso
Journal:  Mem Inst Oswaldo Cruz       Date:  2021-02-03       Impact factor: 2.743

Review 10.  Progress on Poxvirus E3 Ubiquitin Ligases and Adaptor Proteins.

Authors:  Haoran Cui; Yaxian Zhang; Leiliang Zhang
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.